{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:19:35Z","timestamp":1787653175132,"version":"build-2736575974"},"reference-count":33,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Total body irradiation associated with etoposide is widely used in conditioning regimens before hematologic stem cell transplantation (HSCT). The etoposide formulation exposes children to a high dose of ethanol, and data on its side effects are scarce. We investigated whether paediatric patients with acute lymphoid leukaemia and lymphoblastic lymphoma were experiencing hypersensitivity reactions or ethanol-related reactions after etoposide infusion before HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively analyzed all patients treated with a TBI 12 Gy-based-conditioning associated with etoposide 60\u2005mg\/kg before HSCT. Hypersensitivity reactions (tachycardia, hypotension, dyspnea, flushing and erythema) were opposed to ethanol-related symptoms (dizziness, impaired balance) in patients who presented clinical reactions during or after etoposide infusion. Ethanol-induced toxicity risk factors related to demographics and infusion data were analysed such as age, gender, etoposide and ethanol amount, etoposide or ethanol infusion rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between January 2015 and December 2020, 62 patients received etoposide as conditioning regimen and 48 patients were included in the study. The median etoposide dose was 1960\u2005mg (414\u20133600), and the median amount of ethanol in the preparation was 24.3\u2005g (5.1\u201344.6). Twenty patients exhibited etoposide-related symptoms. Eighteen patients presented ethanol-related symptoms, and 2 patients had hypersensitivity reactions and were admitted to the Intensive Care Unit. The incidence of ethanol-related symptoms was significantly higher in patients\u2009\u2265\u20097.5 years old at the time of HSCT (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.04). No other risk factors were found.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data must raise awareness among physicians and pharmacists about the high dose of ethanol to which children are exposed during conditioning, and their adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251330244","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:34:56Z","timestamp":1744817696000},"page":"1032-1039","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ethanol intoxication in paediatric patients receiving intravenous etoposide as conditioning regimen for allogenic hematopoietic stem cell transplant"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5273-2567","authenticated-orcid":false,"given":"Pauline","family":"Claraz","sequence":"first","affiliation":[{"name":"University Robert Debre Hospital"},{"name":"Institut universitaire du cancer Toulouse \u2013 Oncopole"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2492-9802","authenticated-orcid":false,"given":"Marie","family":"de Tersant","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Immunology, University Robert Debre Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Feyants","sequence":"additional","affiliation":[{"name":"University Robert Debre Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Roupret-Serzec","sequence":"additional","affiliation":[{"name":"University Robert Debre Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1738-2191","authenticated-orcid":false,"given":"Thomas","family":"Storme","sequence":"additional","affiliation":[{"name":"University Robert Debre Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Hugues","family":"Dalle","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Immunology, University Robert Debre Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.10.2780.2780"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15761"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9747"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.009"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02529"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00820727"},{"key":"e_1_3_3_8_2","unstructured":"\u00c9toposide - European Pharmacopoeia 11.7 [Internet]. [cited 2024 Dec 21]. Available from: https:\/\/pheur.edqm.eu\/app\/11-7\/content\/11-7\/0823F.htm?highlight=on&terms%5B%5D=%C3%A9toposide&terms%5B%5D=d%E2%80%99%C3%A9toposide&terms%5B%5D=l%E2%80%99%C3%A9toposide"},{"key":"e_1_3_3_9_2","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit - ETOPOSIDE ACCORD 20\u2005mg\/mL solution \u00e0 diluer pour perfusion - Base de donn\u00e9es publique des m\u00e9dicaments [Internet]. [cited 2024 Oct 21]. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=60815657&typedoc=R"},{"key":"e_1_3_3_10_2","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit - ETOPOSIDE MYLAN 20\u2005mg\/ml solution \u00e0 diluer pour perfusion - Base de donn\u00e9es publique des m\u00e9dicaments [Internet]. [cited 2022 Feb 9]. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=69599043&typedoc=R"},{"key":"e_1_3_3_11_2","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit - ETOPOSIDE TEVA 20\u2005mg\/ml solution \u00e0 diluer pour perfusion - Base de donn\u00e9es publique des m\u00e9dicaments [Internet]. [cited 2022 Feb 9]. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=61425560&typedoc=R"},{"key":"e_1_3_3_12_2","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit - ETOPOSIDE HIKMA 20\u2005mg\/ml solution \u00e0 diluer pour perfusion - Base de donn\u00e9es publique des m\u00e9dicaments [Internet]. [cited 2024 Dec 21]. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=66338465&typedoc=R"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2835"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800100280"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.282"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219858390"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155207085355"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010119"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-25.3.175"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00430"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1565"},{"key":"e_1_3_3_22_2","first-page":"212512","article-title":"An overview of exposure to ethanol-containing substances and ethanol intoxication in children based on three illustrated cases","volume":"7","author":"Hon KL","year":"2018","unstructured":"Hon KL, Leung AK, Cheung E, et al. An overview of exposure to ethanol-containing substances and ethanol intoxication in children based on three illustrated cases. Drugs Context 2018; 7: 212512.","journal-title":"Drugs Context"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agt036"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910215)67:4<1070::AID-CNCR2820670434>3.0.CO;2-X"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.6.1080"},{"key":"e_1_3_3_26_2","unstructured":"EMA. Annex to the European Commission guideline on \u2018Excipients in the labelling and package leaflet of medicinal products for human use\u2019 (SANTE-2017-11668) [Internet]. 2019 [cited 2024 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217715790"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000497216"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2014.09.002"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-305671"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2015.05.009"},{"key":"e_1_3_3_32_2","volume-title":"Handbook of pharmaceutical excipients (Rowe, Handbook of Pharmaceutical Excipients)","author":"Rowe RC","year":"2009","unstructured":"Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients (Rowe, Handbook of Pharmaceutical Excipients). 6th ed. London: Pharmaceutical Press and the American Pharmacist Association, 2009, p. 197.","edition":"6"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/children3010001"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.12.003"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251330244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251330244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251330244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:31:50Z","timestamp":1787650310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251330244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552251330244"],"URL":"https:\/\/doi.org\/10.1177\/10781552251330244","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]}}}